

QIBA fMRI Biomarker Committee (BC) Meeting

Wednesday, July 5, 2023, at 11 a.m. (CT)

Meeting Summary

In attendance

Jay Pillai, MD (Co-chair)

David Soltysik, PhD (Co-chair)

Ichiro Ikuta, MD, MMSc

Andrew Kalnin, MD

Anthony Liu, PhD

Nancy Obuchowski, PhD

Judd Storrs, PhD

James Voyvodic, PhD

Francisco Zamorano, PhD

Gudrun Zahlmann, PhD

RSNA staff

Joe Koudelik

Julie Lisiecki

Review of Previous Meeting Summary:

- The 06.21.2023 meeting summary was approved as presented

Topics Discussed:

- Profile updates RSNA Board Directive
 - All RSNA administrative support to end by Dec 22, 2023
 - A new over-arching RSNA Committee to be formed, the Quantitative Imaging Committee, (QUIC)
 - Existing Biomarker Committees welcome to continue independently re: Profile development
 - Professional societies encouraged to maintain BC admin support, e.g., ISMRM, ASFNR

Action Items:

- Actor-specific checklists have been updated
- Performance testing was moved to section 4
- BC plans to reach Stage 1 in Profile development and have a white paper published based on the Profile by December 2023, incorporating a focus on the claims and the reproducibility data
 - Suggestion to publish QIBA Profile-related papers together as a series, similar to metrology papers
 - Consider white paper as a follow up to ASFNR paper on language mapping
- Further discussion needed regarding recommendations for needed improvements to software developers based on QIBA research, with possible incentives
 - Recommendations needed for computing ROI and laterality index
- Profile completion would need to be done well before December to allow for internal review, public comment, Biomarker Committee and Coordinating Committee approval
- Next step will be development of an outline for the suggested white paper; messaging and target audience to be focus of upcoming BC calls

Next Steps

- **Next meeting:** Wednesday, July 19, 2023, at 11 a.m. CT (1st & 3rd weeks of each month)
- Next steps following completion of the Profile:
 - Circulation for full BC internal review followed by a vote-to-release for Stage 1: Public Comment
 - MR CC vote-to-release will follow
- White paper to be drafted once the Profile is completed and Dr. Voyvodic's reproducibility study data has been published